The potential impact of clinical decision support on nonwaivered primary care clinicians' prescribing of buprenorphine.
Health Aff Sch
; 1(4): qxad051, 2023 Oct.
Article
em En
| MEDLINE
| ID: mdl-38756745
ABSTRACT
Elimination of the X-waiver increased potential buprenorphine prescribers 13-fold, but growth in prescribing will likely be much lower. We explored self-assessments of nonwaivered primary care clinicians (PCCs) for factors affecting their likelihood to prescribe buprenorphine were the X-waiver eliminated (since realized January 2023) and the potential impacts of a clinical decision-support (CDS) tool for opioid use disorder (OUD). Cross-sectional survey data were obtained between January 2021 and March 2022 from 305 nonwaivered PCCs at 3 health systems. Factors explored were patient requests for buprenorphine, PCC access to an OUD-CDS, and PCC confidence and abilities for 5 OUD-care activities. Relationships were described using descriptive statistics and odds ratios. Only 26% of PCCs were more likely to prescribe buprenorphine upon patient request, whereas 63% were more likely to prescribe with the OUD-CDS. PCC confidence and abilities for some OUD-care activities were associated with increased prescribing likelihood from patient requests, but none were associated with the OUD-CDS. The OUD-CDS may increase buprenorphine prescribing for PCCs less likely to prescribe upon patient request. Future research is needed to develop interventions that increase PCC buprenorphine prescribing. Clinical trial registration ClinicalTrials.gov. Identifier NCT04198428. Clinical trial name Clinical Decision Support for Opioid Use Disorders in Medical Settings (Compute 2.0).
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Health Aff Sch
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos